NEWS RELEASE

NIPPON SHINYAKU CO., LTD.

March 17, 2022

The result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy

Kyoto, Japan, March 17, 2022 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented about the result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy at the Muscular Dystrophy Association conference from March 13th to 16th.

NS-089/NCNP-02 is an antisense oligonucleotide co-discovered by NCNP and Nippon Shinyaku, and is expected to be a therapeutic drug for Duchenne muscular dystrophy patients who have dystrophin gene mutations that are amenable to exon 44 skipping.

Please check the press release (20220317eng-ncnp-release.pdf) from NCNP for the content of the presentation.

Patients in this Investigator-Initiated Clinical Trial are participating in extension study, and Nippon Shinyaku is planning to investigate the efficacy and safety of longer-term administration. Nippon Shinyaku is also preparing for the next stage of clinical development.

Contact
Corporate Communications Dept., Nippon Shinyaku
FAX: +81-75-321-9128